HERON THERAPEUTICS, INC. /DE/
Price data unavailable
Track HRTX in your trading journalAbout HERON THERAPEUTICS, INC. /DE/
HERON THERAPEUTICS, INC. /DE/ (HRTX) is a publicly listed company on US equity markets.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
The company reports net loss of $8.11M.
Key metrics include a return on equity of -88.8%, a debt-to-equity ratio of 25.95.
Use FINOTAUR to track HRTX's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | — |
| Net Income (TTM) | $-8.11M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -88.77% |
| Debt-to-Equity | 25.95 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·Oct 29
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
- Benzinga·Oct 29
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
- GlobeNewswire Inc.·Sep 17
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR
Want real-time analysis on HRTX?
Track it free in your trading journal. Log trades, tag setups, and review your edge.